Literature DB >> 20429665

Pharmacotherapy strategies in chronic prostatitis/chronic pelvic pain syndrome management.

Adam B Murphy1, Robert B Nadler.   

Abstract

IMPORTANCE OF THE FIELD: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is one of the most common diagnoses arising out of urologic office visits. It is a costly problem and sufferers compare the effect of this syndrome on quality of life as being similar to the effects of diabetes mellitus and myocardial infarction. The syndrome is variable in presentation and symptom management and efficacy will vary between inflicted men. AREAS COVERED IN THIS REVIEW: CP/CPPS is not highly responsive to therapy. As such, it is often a waxing and waning illness with symptoms in multiple domains, including urinary symptoms, pain and ejaculatory dysfunction. The pharmacotherapeutic options and management strategies for CP/CPPS presented in this review are based on the published literature from September 1989 to January 2010. When available, randomized, placebo-controlled studies were reviewed to aid in making definitive recommendations for treatment strategies. WHAT THE READER WILL GAIN: The reader will be familiarized with the commonly used classes of pharmaceutical and non-pharmaceutical therapies. Readers will then use the efficacy data to inform treatment decisions for patients with disparate symptomatology. This will be crystallized in the author's treatment algorithm and summary statement. TAKE HOME MESSAGE: Many practitioners use antimicrobials as a first-line agent, particularly a fluoroquinolone, such as levofloxacin. Trimethoprim/sulfamethoxazole is another medication alternative, with comparable response rates. Many afflicted men will have significant improvement on a 4- to 6-week regimen of a fluoroquinolone antibiotic. Second-line pharmacotherapy includes alpha-blockers, 5-alpha reductase inhibitors and anti-inflammatories for men with urinary symptoms or pain as a predominant symptom domain. Other pharmacotherapy includes steroids, glycosaminoglycans and phytotherapy. Surgical options are generally not recommended for CP/CPPS. Despite the lack of curative therapies, effective symptom management can be achieved with knowledge of the classes of pharmacotherapy. Therapeutic decisions can be based on the symptoms of the patient. Pelvic floor physical therapy is a useful second-line therapy in the author's opinion, but randomized controlled trials and standardization of technique for CP/CPPS are needed before recommendations can be substantiated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20429665     DOI: 10.1517/14656561003709748

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  9 in total

Review 1.  An overview of prostate diseases and their characteristics specific to Asian men.

Authors:  Shu-Jie Xia; Di Cui; Qi Jiang
Journal:  Asian J Androl       Date:  2012-02-06       Impact factor: 3.285

2.  [Chronic pelvic pain syndrome : Treatment options using osteopathy].

Authors:  S Marx
Journal:  Urologe A       Date:  2017-08       Impact factor: 0.639

Review 3.  Pelvic floor therapies in chronic pelvic pain syndrome.

Authors:  Ragi Doggweiler; Adam F Stewart
Journal:  Curr Urol Rep       Date:  2011-08       Impact factor: 3.092

4.  Oral pharmacological treatments for chronic prostatitis/chronic pelvic pain syndrome: A systematic review and network meta-analysis of randomised controlled trials.

Authors:  Zongshi Qin; Chao Zhang; Jianbo Guo; Joey S W Kwong; Xiao Li; Ran Pang; R Christopher Doiron; J Curtis Nickel; Jiani Wu
Journal:  EClinicalMedicine       Date:  2022-05-20

Review 5.  Chronic prostatitis/chronic pelvic pain syndrome: a review of evaluation and therapy.

Authors:  A S Polackwich; D A Shoskes
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-03-08       Impact factor: 5.554

6.  Multi-factors including Inflammatory/Immune, Hormones, Tumor-related Proteins and Nutrition associated with Chronic Prostatitis NIH IIIa+b and IV based on FAMHES project.

Authors:  Yang Chen; Jie Li; Yanling Hu; Haiying Zhang; Xiaobo Yang; Yonghua Jiang; Ziting Yao; Yinchun Chen; Yong Gao; Aihua Tan; Ming Liao; Zhen Lu; Chunlei Wu; Xiaoyin Xian; Suchun Wei; Zhifu Zhang; Wei Chen; Gong-Hong Wei; Qiuyan Wang; Zengnan Mo
Journal:  Sci Rep       Date:  2017-08-22       Impact factor: 4.379

7.  Phosphodiesterase type 5 inhibitor therapy provides sustained relief of symptoms among patients with chronic pelvic pain syndrome.

Authors:  Kevin Pineault; Shagnik Ray; Andrew Gabrielson; Amin S Herati
Journal:  Transl Androl Urol       Date:  2020-04

8.  Network Meta-Analysis of the Efficacy of Acupuncture, Alpha-blockers and Antibiotics on Chronic Prostatitis/Chronic Pelvic Pain Syndrome.

Authors:  Zongshi Qin; Jiani Wu; Jinhui Tian; Jing Zhou; Yali Liu; Zhishun Liu
Journal:  Sci Rep       Date:  2016-10-19       Impact factor: 4.379

9.  Flower Pollen Extract in Association with Vitamins (Deprox 500®) Versus Serenoa repens in Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Comparative Analysis of Two Different Treatments.

Authors:  Nicola Macchione; Paolo Bernardini; Igor Piacentini; Barbara Mangiarotti; Alberto Del Nero
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2019
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.